Skip to main
QNCX
QNCX logo

QNCX Stock Forecast & Price Target

QNCX Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Quince Therapeutics Inc. demonstrates a promising outlook due to a strong safety record revealed through prior clinical trials and open-label extensions, which instills confidence in the long-term tolerability of its therapies. The firm has also validated its drug platform's efficacy by confirming a sustained-release profile that mitigates typical safety concerns associated with chronic therapies, particularly for corticosteroids. Additionally, the scalability indicated by the two-compartment model fitting diverse patient data suggests that Quince's innovative therapies have the potential for widespread application in treating debilitating and rare diseases.

Bears say

Quince Therapeutics is currently operating at the preclinical stage, which presents inherent risks and uncertainties regarding the advancement of its drug candidates into clinical trials, potentially delaying revenue generation. The company's pipeline is focused on niche indications, such as Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, which may limit its market size and overall growth potential. Additionally, the need for substantial funding to support ongoing research and development activities raises concerns about financial sustainability and the ability to achieve commercialization in the future.

QNCX has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quince Therapeutics Inc (QNCX) Forecast

Analysts have given QNCX a Strong Buy based on their latest research and market trends.

According to 7 analysts, QNCX has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quince Therapeutics Inc (QNCX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.